Alnylam Pharmaceuticals Inc (ALNY) — Capital Reinvestment Ratio
Alnylam Pharmaceuticals Inc (ALNY) has a Capital Reinvestment Ratio of 0.14x as of December 2025, meaning it reinvests 0% of its operating cash flow ($163.56 Million) in capital expenditures ($23.29 Million). See ALNY net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Alnylam Pharmaceuticals Inc Capital Reinvestment Ratio (2007–2025)
This chart tracks Alnylam Pharmaceuticals Inc's Capital Reinvestment Ratio across 4 annual periods. Check Alnylam Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc (2007–2025)
Year-by-year Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc from 2007 to 2025. For live market cap and broader valuation context, see ALNY company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | $524.08 Million | $58.70 Million | ▼ -81.2% |
| 2023 | 0.60x | $104.16 Million | $62.21 Million | ▲ +263.4% |
| 2008 | 0.16x | $65.49 Million | $10.76 Million | ▲ +314.7% |
| 2007 | 0.04x | $196.52 Million | $7.79 Million | — |